One of the leading Japanese shosha (general trading company) announced that in 20:80 partnership with a large foreign biotech-oriented venture fund has set up a service company under the apt name JapanBridge.
In the past three decades, an untold number of "Japan-bridging" companies were planned, set up and even still existed by entrepreneurs from both sides of the Atlantic (in the spirit of full disclosure, those included some of our founders).
What should be made the new JapanBridge different aside from the 100 million US$ expected to be pumped into the new entity within 3 years? The current answer is the new formula - taking only late clinical stage compounds from early stage biotech companies.
Jouhoublog is a joint blog - post or send comments to .
Technorati Tags: MHLW; Japanese regulatory affairs